Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Propionic Acidemia Market size was valued at USD 2.08 billion in 2024 and is likely to cross USD 3.09 billion by 2037, registering more than 3.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of propionic acidemia is assessed at USD 2.13 billion.
One important factor that will help the market to grow over the forecast period is an increase in prevalence of propionic acidemia. For instance, according to the article published in NCBI Propionic acidemia affects about 1 in 100,000 people in the United States. In some populations, such as Greenland's Inuit population and certain amish communities in Saudi Arabia, the condition seems to be more common. Moreover, propionic acidemia market growth will also be driven by an increasing number of treatment options and a rise in the incidence of ketotic hyperglycaemia and others.
The efficacy and patient compliance of the treatment is enhanced by technological advances in drug delivery systems and formulation. In addition, improved access to healthcare for patients with uncommon diseases such as propionic acidemia is facilitated by the growing use of telemedicine and Digital Health Platforms.
Propionic Acidemia Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Awareness About Propionic Acidemia – Growing public awareness campaigns and initiatives are raising awareness of PA globally, leading to earlier diagnosis and treatment. Increased media coverage and patient advocacy groups are contributing the destigmatization and increasing public understanding of the conditions.
- Increasing Demand for Personalized Medicine – The rise of personalized medicine is driving the development of targeted therapies tailored to individual patient needs and genetic variations. This personalized approach holds promise for improved treatment efficacy and reduced side effects in PA patients.
Challenges
- High Cost of Treatment – Carnitine supplements a mainstay of PA treatment can cost thousands of dollars per month. Newer therapies such as gene therapy and enzyme replacement therapy are expected to be even more expensive, creating affordability issues for many families.
- Limited Access to Healthcare is anticipated to hamper the propionic acidemia market growth in the upcoming period.
- Limited Research and Development is Expected to Hinder the market expansion in the projected period.
Propionic Acidemia Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024 - 2036 |
|
CAGR |
~4% |
|
Base Year Market Size (2023) |
~USD 2 Billion |
|
Forecast Year Market Size (2036) |
~USD 45 Billion |
|
Regional Scope |
|
Propionic Acidemia Segmentation
Drug Class (L-Carnitine, Antibiotics)
In terms of drug class, L-carnitine segment is estimated to hold 70% share of the global propionic acidemia market by 2037. L-carnitine is a chemical that's produced in the human brain, liver and kidneys. It's helping the body to make energy out of fat. L-carnitine is a vital element for the health of the heart and brain, muscle activity as well as many different processes in the body. The body is capable of converting L-carnitine into other chemicals called acetylcarnitine, and propionyl. In three patients with Propionic Acidemia and in 3 standard controls, L-Carnitine significantly increased the formation and excretion of short chain acylcarnitine. Acylcarnitine has been found to be propionylcarnitine in patients with proionic acidemia by the use of rapid atom bombardment mass spectrometry and a correlation scan at constant magnet-to-electric field ratio. Mostly acetylcarnitine was absorbed by the normal children.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Based on distribution channel, the retail pharmacy segment is expected to hold a notable share of the global propionic acidemia market by 2037. When patients are discharged from hospital, retail pharmacies play an important role in supplying them with medicinal products. Retail pharmacies offer convenient access to essential medications such as carnitine supplements, vitamins and antibiotics for managing PA symptoms. This can be particularly beneficial for patients in remote areas or those who struggle with transportation to specialized clinics. Retail chains are the biggest and most predominant of the four drug store sorts, speaking to a third of stores and around a third of medicine incomes in 2021.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPropionic Acidemia Industry-Regional Synopsis
North American Market Forecasts
North America industry is likely to dominate majority revenue share of 35% by 2037, This growth can be attributed to improved healthcare infrastructure, FDA approvals, increased prevalence of propionic acidemia, collaboration and acquisitions with key players and others expected to dominate this region during the forecast period. For example, an orphan drug designation for AAV9hPCCA for the treatment of propionic acidemia was granted by the FDA to the National Center for Advancing Translational Sciences in May 2022.
APAC Market Statistics
The propionic acidemia market in the Asia Pacific region is set to grow significantly during the time period between 2025-2037. Newborn screening programs are essential for early diagnosis of propionic acidemia, as early intervention can significantly enhance patient outcomes. The adoption of newborn screening programs is increasing in the Asia Pacific region, which is anticipated to lead toa rise in diagnosed cases of propionic acidemia and consequently the propionic acidemia market.
Companies Dominating the Propionic Acidemia Landscape
- Cardiva Grifols SA
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CSL Behring
- Octapharma AG
- Sanquin
- Kedrion SpA
- Shire
- China Biologic Products Holdings Inc.
- Teva Pharmaceuticals
- Wellona Pharma
- Merck
- AdvaCare Pharma
In the News
- In May 2023, Moderna, Inc, a biotechnology company pioneering courier RNA (mRNA) therapeutics and immunizations, expressed that an unique announcing on between times information from the Stage I/II trial of mRNA-3927, an investigational mRNA treatment for propionic acidemia has been acknowledged for introduction at the 2023 American Society of Quality + Cell Treatment Yearly Assembly being held May 16-20, 2023 in Los Angeles, CA.
- In Eminent 2022, BridgeBio Pharma expressed the Dosing of the Primary Understanding within the Stage I Trial of BBP-671, a Potential best-in-class treatment for propionic acidemia and methylmalonic acidemia (MMA)BBP-671 is an investigational verbal treatment expecting to extend CoA levels by allosterically balancing pantothenate kinases, key proteins within the CoA biosynthesis pathway.
Author Credits: Rajrani Baghel
- Report ID: 5773
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
